IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT06257823 (ENIGMA) pour Accident vasculaire cérébral ischémique, Accident ischémique transitoire est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Vascular Cognitive Decline and Dementia (ENIGMA)
Cerebral capillary dysfunction is characterized by limited oxygen extraction from the brain capillaries due to age- and risk factor-related capillary flow heterogeneity. Capillary dysfunction is a pathophysiological feature of cerebral small vessel disease (cSVD) and may play an important role in the vascular mechanisms underlying PSCI. Extracellular vesicles (EVs) carry molecules between cells. EV profiles may change during acute stroke, in the chronic stroke phase, and according to the level of cSVD, and EV profiles may therefore act as disease biomarkers.
The ENIGMA study aims to investigate capillary dysfunction and EV profiles as predictors of cognitive function one year after acute ischemic stroke (AIS) and transient ischemic attack (TIA). Consecutive patients with AIS and TIA are included and followed for one year with follow-up visits at three and 12 months. An MRI is performed at 24 hours and 12 months after admission. EV profiles will be characterised from blood samples drawn at 24 hours and three months after admission. Cognitive function is assessed three and 12 months after AIS and TIA using the Repeatable Battery for the Assessment of Neuropsychological Status and the Montreal Cognitive Assessment (MoCA).
The study has two main objectives: 1) to study associations between capillary dysfunction and PSCI and 2) to assess associations between EV profiles and PSCI.
Exploring Vascular Contributions to Cognitive Decline and Dementia
- ENIGMA
- 1-10-72-253-20
Cognitive impairment
MRI
Extracellular vesicles
Stroke
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
N/A | AUCUNE INTERVENTION No intervention |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Post-stroke cognitive decline | Change in RBANS index score from three to 12 months follow-up | 12 months |
Post-stroke cognitive impairment | Total RBANS index score | 12 months |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Post-stroke cognitive decline | Change in MoCA score from three to 12 months follow-up | 12 months |
Post-stroke cognitive impairment | MoCA score at 12 months follow-up | 12 months |
Post-stroke depression | Measured on the major depression inventory | 12 months |
Physical activity | Measured on the Physical Activity Scale for the Elderley | 12 months |
- AIS or TIA with a clinically relevant diffusion restriction identified on MRI DWI-sequence on admission
- Admittance within 24 hours from symptom onset
- Age ≥ 60
- Dependency in activities of daily living (mRS score > 2)
- Known dementia, neurodegenerative disease, or other significant brain disease
- Concomitant life-threatening disease
- Contraindications to undergo MRI
- Allergy or intolerance to MRI contrast agents
- eGFR < 30
- Unable to give written informed consent
- Deemed unfit for follow-up